journal article·2023-04Open access

Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8+ T Cells

Jiacheng Bi, Xiaomeng Jin, Chaoyue Zheng, Chen Huang, Chao Zhong, Xiaohu Zheng, Zhigang Tian, Haoyu Sun

Advanced Science· Volume 10· Issue 12

Abstract

Abstract Natural killer (NK) cells not only are innate effector lymphocytes that directly participate in tumor surveillance but are also essential helpers in the antitumor CD8+ T‐cell response. However, the molecular mechanisms and potential checkpoints regulating NK cell helper functions remain elusive. Here, it is shown that the T‐bet/Eomes‐IFN‐γ axis in NK cells is essential for CD8+ T cell‐dependent tumor control, whereas T‐bet‐dependent NK cell effector functions are required for an optimal response to anti‐PD‐L1 immunotherapy. Importantly, NK cell‐expressed TIPE2 (tumor necrosis factor‐alpha‐induced protein‐8 like‐2) represents a checkpoint molecule for NK cell helper function, since Tipe2 deletion in NK cells not only enhances NK‐intrinsic antitumor activity but also indirectly improves the antitumor CD8+ T cell response by promoting T‐bet/Eomes‐dependent NK cell effector functions. These studies thus reveal TIPE2 as a checkpoint for NK cell helper function, whose targeting might boost the antitumor T cell response in addition to T cell‐based immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immune Cell Function and Interaction · CAR-T cell therapy research · T-cell and B-cell Immunology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The CAS Key Laboratory of Quantitative Engineering Biology Shenzhen Institute of Synthetic Biology Shenzhen Institute of Advanced Technology Chinese Academy of Sciences Shenzhen 518055 P. R. China

Institute of Systems Biomedicine School of Basic Medical Sciences Peking University Health Science Center Beijing 100191 P. R. China

The CAS Key Laboratory of Innate Immunity and Chronic Disease School of Basic Medical Sciences, Division of Life Sciences and Medicine University of Science and Technology of China Hefei 230027 P. R. China

Institute of Immunology University of Science and Technology of China Hefei 230027 P. R. China

Research Unit of NK cell Study Chinese Academy of Medical Sciences Beijing 100864 P. R. China

Funding

National Natural Science Foundation of China

References (41)

Show source-provided references
1. 10.1038/ni158210.1038/ni1582 ↗
2. 10.1016/j.celrep.2020.10772010.1016/j.celrep.2020.107720 ↗
3. 10.1016/S1074-7613(04)00076-710.1016/S1074-7613(04)00076-7 ↗
4. 10.1038/s41568-020-0272-z10.1038/s41568-020-0272-z ↗
5. 10.1038/s41590-020-0728-z10.1038/s41590-020-0728-z ↗
6. 10.1038/3218310.1038/32183 ↗
7. 10.1084/jem.2001114910.1084/jem.20011149 ↗
8. 10.1084/jem.2001093810.1084/jem.20010938 ↗
9. 10.1016/j.celrep.2019.08.01710.1016/j.celrep.2019.08.017 ↗
10. 10.1038/s41591-018-0085-810.1038/s41591-018-0085-8 ↗
11. 10.1038/s41590-018-0132-010.1038/s41590-018-0132-0 ↗
12. 10.1136/jitc-2020-00193310.1136/jitc-2020-001933 ↗
13. 10.3389/fimmu.2019.0199910.3389/fimmu.2019.01999 ↗
14. 10.1182/blood-2012-03-41536410.1182/blood-2012-03-415364 ↗
15. 10.1016/j.cell.2008.03.02610.1016/j.cell.2008.03.026 ↗
16. 10.1073/pnas.120452510910.1073/pnas.1204525109 ↗
17. 10.1371/journal.pone.009650810.1371/journal.pone.0096508 ↗
18. 10.1084/jem.2018200510.1084/jem.20182005 ↗
19. 10.1126/sciadv.abi651510.1126/sciadv.abi6515 ↗
20. 10.1101/cshperspect.a02848010.1101/cshperspect.a028480 ↗
21. 10.1080/0883018090297812010.1080/08830180902978120 ↗
22. 10.1016/j.imlet.2004.05.00310.1016/j.imlet.2004.05.003 ↗
23. 10.1016/j.cell.2022.09.02010.1016/j.cell.2022.09.020 ↗
24. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
25. 10.4049/jimmunol.150084610.4049/jimmunol.1500846 ↗
26. 10.1038/cmi.2017.1010.1038/cmi.2017.10 ↗
27. 10.1128/JVI.00365-0810.1128/JVI.00365-08 ↗
28. 10.1128/IAI.73.8.4913-4921.200510.1128/IAI.73.8.4913-4921.2005 ↗
29. 10.1073/pnas.181464211610.1073/pnas.1814642116 ↗
30. 10.1073/pnas.130102211010.1073/pnas.1301022110 ↗
31. 10.1038/s41418-020-00715-610.1038/s41418-020-00715-6 ↗
32. 10.1038/s41467-018-07277-910.1038/s41467-018-07277-9 ↗
33. 10.1084/jem.2014170310.1084/jem.20141703 ↗
34. 10.4049/jimmunol.160107810.4049/jimmunol.1601078 ↗
35. 10.1038/ncomms1273010.1038/ncomms12730 ↗
36. 10.1016/j.molimm.2017.03.00710.1016/j.molimm.2017.03.007 ↗
37. 10.18632/oncotarget.1140610.18632/oncotarget.11406 ↗
38. 10.1371/journal.pone.012617610.1371/journal.pone.0126176 ↗
39. 10.1038/sj.gt.330246910.1038/sj.gt.3302469 ↗
40. 10.1038/sj.gt.330221010.1038/sj.gt.3302210 ↗
41. 10.1128/JVI.77.16.8957-8951.200310.1128/JVI.77.16.8957-8951.2003 ↗